Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2007; 13(12): 1841-1846
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1841
Immunoscintigraphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58
Yun-Feng Yao, Zhi Yang, Zhen-Fu Li, Jin Gu
Yun-Feng Yao, Zhi Yang, Zhen-Fu Li, Jin Gu, Peking University School of Oncology, Beijing 100036, China
Author contributions: All authors contributed equally to the work.
Supported by National High-Tech R&D Program of China (863 Program), No. 2004AA215270
Correspondence to: Dr. Jin Gu, Peking University School of Oncology, Fucheng Road #52, Haidian District, Beijing 100036, China. zlguj@bjmu.edu.cn
Telephone: +86-10-88141032 Fax: +86-10-88141032
Received: December 1, 2006
Revised: December 7, 2006
Accepted: January 26, 2007
Published online: March 28, 2007
Abstract

AIM: To explore a specific diagnostic method for local recurrent rectal cancer.

METHODS: Immunoscintigraphy with 99mTc-labeled anti-CEA monoclonal antibody (MoAb) CL-58 was performed for patients suspected of having a postoperative local recurrent rectal cancer and the findings were compared with the results of conventional imaging and pathology.

RESULTS: A total of 36 patients with a suspected local recurrent rectal cancer underwent immunoscintigraphy with 99mTc-conjugated CL58. Local recurrence of rectal cancer was identified in 31 patients and established in 30 during operation, endoscopy and pathological examination. No local recurrence was found in 5 patients without specific accumulation of 99mTc during the follow-up. Immunoscintigraphy had a positive rate of 86.11%, a specificity of 83.33%, and a sensitivity of 100%.

CONCLUSION: Immunoscintigraphy has a highly specific and predictive value for detecting local recurrent rectal cancer, especially after abdominal perineal resection (APR).

Keywords: Immunoscintigraphy; Rectal cancer; Recurrence; Monoclonal antibody